Journal article
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin
Anti-cancer drugs, Vol.21(3), pp.313-319
03/2010
DOI: 10.1097/CAD.0b013e328334d88a
PMID: 20016369
Abstract
The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer. A secondary endpoint was to investigate the correlation between thymidylate synthase and thymidine phosphorylase (TP) expression in metastatic tissues and tumor response. Forty-one patients received oral capecitabine 1331 mg/m(2) every day combined with intravenous oxaliplatin 85 mg/m(2) every 2 weeks. The overall response rate was 58.5% [95% confidence interval (CI): 43.3-73.6%], the median progression-free survival 9.4 months ( 95% CI: 7.7-11.2 months) and the median survival 22.3 months (95% CI: 16.1-27.5 months). There were no grade 4 toxicities, and grade 3 toxicity was also uncommon. High TP expression in metastatic tissue was significantly associated with response to treatment (P = 0.019), and also with a trend towards a better median progression-free survival and overall survival compared with patients expressing low TP (P = 0.056; P = 0.073). This study suggests that biweekly oxaliplatin and continuous oral capecitabine is an active and well-tolerated chemotherapy regimen in the first-line treatment of metastatic colorectal cancer. Moreover, these findings add to a growing body of evidence that patients with high levels of intratumoral TP expression are the ideal candidates for capecitabine-based chemotherapy. Anti-Cancer Drugs 21: 313-319 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Details
- Title: Subtitle
- Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin
- Creators
- Roberto Petrioli - University of SienaGianluca Bargagli - University of SienaStefano Lazzi - University of SienaAlessandra Pascucci - University of SienaEdoardo Francini - University of SienaCristiana Bellan - University of SienaRaffaele Conca - University of SienaIgnazio Martellucci - University of SienaAnna Ida Fiaschi - University of SienaBruno Lorenzi - University of SienaGuido Francini - University of SienaMultidisciplinary Oncology Grp Gas
- Resource Type
- Journal article
- Publication Details
- Anti-cancer drugs, Vol.21(3), pp.313-319
- DOI
- 10.1097/CAD.0b013e328334d88a
- PMID
- 20016369
- ISSN
- 0959-4973
- eISSN
- 1473-5741
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 7
- Language
- English
- Date published
- 03/2010
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221244902771
Metrics
1 Record Views